Patient-Reported Outcomes And Quality Of Life Improvements In Patients With Asthma Receiving A New, Breath-Actuated Beclomethasone Dipropionate Inhaler

Methods Phase 3, 6-week, randomized, double-blind, placebo-controlled trial (NCT02513160) evaluated efficacy and safety of BDP BAI in persistent asthmatic patients >=12 years. Patient-reported outcomes included: change from baseline in Asthma Control Questionnaire-6 (ACQ-6) and Asthma Quality of Life Questionnaire with Standardized Activities score (AQLQ[S]) at week 6 and treatment endpoint and change from baseline in Asthma Control Test (ACT) at week 6 and treatment endpoint.